PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(14)61399-4 ◽

2015 ◽

Vol 385 (9965) ◽

pp. 331-340 ◽

Author(s):

Frederick J Raal ◽

Evan A Stein ◽

Robert Dufour ◽

Traci Turner ◽

Fernando Civeira ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Pcsk9 Inhibition ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Faculty Opinions recommendation of Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718277738.793491004 ◽

2014 ◽

Author(s):

Andrew Tonkin

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Anacetrapib as Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolaemia (REALIZE): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study

Journal of Vascular Surgery ◽

10.1016/j.jvs.2016.02.008 ◽

2016 ◽

Vol 63 (4) ◽

pp. 1127-1128

Author(s):

J.J. Kastelein ◽

J. Besseling ◽

S. Shah

Keyword(s):

Familial Hypercholesterolaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(10)60284-x ◽

2010 ◽

Vol 375 (9719) ◽

pp. 998-1006 ◽

Author(s):

Frederick J Raal ◽

Raul D Santos ◽

Dirk J Blom ◽

A David Marais ◽

Min-Ji Charng ◽

...

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

PCSK9 Inhibition With Evolocumab (AMG 145) in Heterozygous Familial Hypercholesterolemia (RUTHERFORD-2): A Randomised, Double-Blind, Placebo-Controlled Trial

Journal of Vascular Surgery ◽

10.1016/j.jvs.2015.09.006 ◽

2015 ◽

Vol 62 (5) ◽

pp. 1368 ◽

Author(s):

F.J. Raal ◽

E.A. Stein ◽

R. Dufour

Keyword(s):

Familial Hypercholesterolemia ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolemia ◽

Pcsk9 Inhibition

Download Full-text

Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia

Atherosclerosis ◽

10.1016/0021-9150(85)90097-8 ◽

1985 ◽

Vol 55 (2) ◽

pp. 187-194 ◽

Author(s):

P.N. Durrington ◽

J.P. Miller

Keyword(s):

Familial Hypercholesterolaemia ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

10.1016/s0140-6736(14)62115-2 ◽

2015 ◽

Vol 385 (9983) ◽

pp. 2153-2161 ◽

Author(s):

John J P Kastelein ◽

Joost Besseling ◽

Sukrut Shah ◽

Jean Bergeron ◽

Gisle Langslet ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Yearbook of Pediatrics ◽

10.1016/s0084-3954(10)79782-7 ◽

2011 ◽

Vol 2011 ◽

pp. 454-455

Author(s):

J.A. Stockman

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(14)61374-x ◽

2015 ◽

Vol 385 (9965) ◽

pp. 341-350 ◽

Author(s):

Frederick J Raal ◽

Narimon Honarpour ◽

Dirk J Blom ◽

G Kees Hovingh ◽

Feng Xu ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

Clinical & Experimental Allergy ◽

10.1046/j.1365-2222.1997.1220903.x ◽

1997 ◽

Vol 27 (8) ◽

pp. 860-867 ◽

Author(s):

V.A. VARNEY ◽

J. EDWARDS ◽

K. TABBAH ◽

H. BREWSTER ◽

G. MAVROLEON ◽

...

Keyword(s):

Clinical Efficacy ◽

Specific Immunotherapy ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized double blind, placebo controlled trial of a Chinese herbal preparation (CH100) in chronic Hepatitis C

Gastroenterology ◽

10.1016/s0016-5085(01)81907-7 ◽

2001 ◽

Vol 120 (5) ◽

pp. A384-A384

Author(s):

L MOLLISON ◽

L TOTTEN ◽

C HOVELL ◽

K THAYNE ◽

C CONNELLY ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Controlled Trial ◽

Herbal Preparation ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text